1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Alvogen Acquires Assertio Therapeutics - Gralise Business

M&A Deal Summary

Alvogen Acquires Assertio Therapeutics - Gralise Business

On January 13, 2020, Alvogen acquired life science company Assertio Therapeutics - Gralise Business from Assertio for 128M USD

Acquisition Highlights
  • This is Alvogen’s 8th transaction in the Life Science sector.
  • This is Alvogen’s 2nd largest (disclosed) transaction.
  • This is Alvogen’s 3rd transaction in the United States.
  • This is Alvogen’s 1st transaction in California.

M&A Deal Summary
Date 2020-01-13
Target Assertio Therapeutics - Gralise Business
Sector Life Science
Buyer(s) Alvogen
Sellers(s) Assertio
Deal Type Divestiture
Deal Value 128M USD

Target

Assertio Therapeutics - Gralise Business

Newark, California, United States
Assertio Therapeutics, Inc. - Gralise Business is a prescription medicine used to treat pain after shingles, or postherpetic neuralgia (PHN).

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alvogen

Pine Brook, New Jersey, United States
Category Company
Founded 2009
Sector Life Science
DESCRIPTION

Alvogen is a multinational pharmaceuticals company focused on developing, manufacturing, and distributing generic, brand, over-the-counter brands (OTC), and biosimilar products. Alvogen was founded in 2009 and is based in Pine Brook, New Jersey.

DEAL STATS #
Overall 8 of 8
Sector: Life Science M&A 8 of 8
Type: Divestiture M&A Deals 4 of 4
State: California M&A 1 of 1
Country: United States M&A 3 of 3
Year: 2020 M&A 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-25 Alvogen CEE

Poland

Alvogen CEE markets over 200 generic and over-the-counter products across multiple therapeutic areas, consisting of highly recognized brands like Lactacyd, Persen, EuBiotic and many more with leading market positions in 14 key markets across CEE including; Russia, Romania, Bulgaria, Hungary, Poland and Balkan markets.

Sell -

Seller(S) 1

SELLER

Assertio

Lake Forest, Illinois, United States
Category Company
Founded 1995
Sector Life Science
Employees58
Revenue 125M USD (2024)
DESCRIPTION

Assertio is a pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. Assertio was founded in 1995 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 2 of 3
Sector: Life Science M&A 1 of 2
Type: Divestiture M&A Deals 2 of 3
State: California M&A 1 of 2
Country: United States M&A 2 of 3
Year: 2020 M&A 1 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-04 Depomed - Diabetes Royalty Rights

United States

Depomed - Diabetes Royalty Rights is a provider of medical products.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-06 Assertio Therapeutics - NUCYNTA

California, United States

Assertio Therapeutics, Inc. - NUCYNTA is a strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short-term (acute) pain in adults when other pain treatments, such as non-opioid pain medicines, do not treat your pain well enough or you cannot tolerate them.

Sell $375M
Mergr

Solution for

Product

Company

Legal